ondansetron has been researched along with Harelip in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron is increasingly used off label to treat nausea and vomiting during pregnancy." | 9.05 | Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. ( Berard, A; Cottin, J; Cucherat, M; Grenet, G; Picot, C; Ripoche, E, 2020) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 8.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 8.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "Ondansetron is increasingly used off label to treat nausea and vomiting during pregnancy." | 5.05 | Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. ( Berard, A; Cottin, J; Cucherat, M; Grenet, G; Picot, C; Ripoche, E, 2020) |
| "Although there is no recommendation in France relating to the treatment of nausea and vomiting of pregnancy, there are some in other countries, where ondansetron, widely used, appears to be an effective second-line treatment option behind doxylamine/vitamin B6 association and metoclopramide." | 4.02 | [Nausea and vomiting in pregnancy: A place for ondansetron?] ( Coulm, B, 2021) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 4.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting." | 3.88 | Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. ( Bateman, BT; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Straub, L; Zhu, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Coulm, B | 1 |
| Huybrechts, KF | 2 |
| Hernandez-Diaz, S | 3 |
| Straub, L | 2 |
| Gray, KJ | 2 |
| Zhu, Y | 2 |
| Mogun, H | 2 |
| Bateman, BT | 2 |
| Picot, C | 1 |
| Berard, A | 1 |
| Grenet, G | 1 |
| Ripoche, E | 1 |
| Cucherat, M | 1 |
| Cottin, J | 1 |
| Damkier, P | 1 |
| Kaplan, YC | 1 |
| Shechtman, S | 1 |
| Diav-Citrin, O | 1 |
| Cassina, M | 1 |
| Weber-Schoendorfer, C | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Míguez Fortes, L | 1 |
| Lema Carril, A | 1 |
| Gómez Tellado, M | 1 |
| Casal Beloy, I | 1 |
| Blanco Portals, C | 1 |
| García González, M | 1 |
| Rodríguez Ruiz, M | 1 |
| Somoza Argibay, I | 1 |
| Dargallo Carbonell, T | 1 |
| Anderka, M | 1 |
| Mitchell, AA | 1 |
| Louik, C | 1 |
| Werler, MM | 1 |
| Rasmussen, SA | 1 |
1 review available for ondansetron and Harelip
| Article | Year |
|---|---|
Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Ondansetron; Preg | 2020 |
6 other studies available for ondansetron and Harelip
| Article | Year |
|---|---|
[Nausea and vomiting in pregnancy: A place for ondansetron?]
Topics: Antiemetics; Cleft Lip; Cleft Palate; Female; Humans; Nausea; Ondansetron; Pregnancy; Vomiting | 2021 |
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antiemetics; Cleft Lip; Cleft Palate; Fema | 2020 |
Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC).
Topics: Antiemetics; Cleft Lip; Cleft Palate; Contraindications, Drug; Drug Labeling; European Union; Female | 2021 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
[Parent controled analgesia system in postoperative pain management in patients undergoing lip and cleft palate surgery].
Topics: Analgesia, Patient-Controlled; Child, Preschool; Cleft Lip; Cleft Palate; Dipyrone; Female; Humans; | 2019 |
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Cleft Lip; Cleft Palate; Female; Humans; H | 2012 |